TXMD News - Candlesense

TherapeuticsMD Announces Second Quarter 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results ...

What is the expected impact of macro‑economic trends on the company’s royalty revenue? Is there any indication of a potential acquisition or partnership in the pipeline? What is the company's guidance on capital expenditures for the remainder of 2025?

Earnings

26 days ago